Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

Impact · against what's priced in

Ultragenyx secures a $210 million cash influx from the sale of a Priority Review Voucher. While the existence of the voucher was known, the market had not yet assigned value to it, and the proceeds specifically mitigate the risk of near-term equity dilution.

RARE+0.40: Challenges what's priced in
The price assumes: The value of the Priority Review Voucher received with FAYUVI, which provides a one-time cash windfall the market has not fully absorbed.
The sale of the PRV for $210 million converts a theoretical asset into actual cash, providing non-dilutive funding that reduces the need for equity financing.
What RARE's price assumes · Sep 22

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARENew
pharmaceuticals
biotech
asset sale
fda
non dilutive funding
priority review voucher
rare disease

Top 1 mover · tap to explore

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

What matters in this story

How each ticker is affected

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

What matters in this story

How each ticker is affected

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Track these names every morning.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

What matters in this story

How each ticker is affected

Next reads from the same story arc

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

What matters in this story

How each ticker is affected

Next reads from the same story arc

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Track these names every morning.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies